Value
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.7 |
| P/S | 5.0 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 5.0 |
| PEG | 4.5 |
| Analyst target | 6.0 |
- ▸Forward P/E: 25.1x
- ▸PEG: 2.04
EW · Why this verdict
Why Edwards Lifesciences Corporatio (EW) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Edwards Lifesciences carries best-in-class margins and a consistent earnings beat pattern, but a forward multiple of 25.6x combined with price momentum below the acceptable threshold, a 74% product concentration in a single franchise, and only about 1% headroom to the near-term price target create a risk/reward profile that does not justify adding to the position at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Gross and operating margins both score at their maximum level with a Piotroski F-Score of 8 out of 9, placing this among the highest-quality franchises in the medical device space and providing meaningful cushion against temporary revenue setbacks. Quality breakdown | Margins noted as strong at the 17% level are maintained or improved over the next 12 months, and the Piotroski F-Score remains at 7 or above, confirming durable financial health. | →Stable |
| CounterA product revenue concentration of 74% in a single franchise means any clinical complication, regulatory action, or competitive entry affecting that category could compress these margins sharply, with limited business diversification to absorb the impact. | ||
With approximately 74% of revenues concentrated in one product category and 58% in a single geography, any clinical setback, reimbursement change, or competitive displacement in the core franchise would have an outsized impact on overall results with no material offset from other lines of business. Bear case | Revenue from the leading product category declines to represent less than 65% of total sales within 2 fiscal years as the broader portfolio grows, reducing single-product dependency. | ↑Improving |
| CounterThe bull case highlights a high-quality business, and best-in-class margins among peers suggest the leading product has established durable commercial economics that may limit the likelihood of rapid substitution. | ||
Price momentum has fallen to 3.2, below the 4.5 acceptable threshold, while volume is flowing out of the stock — a deteriorating technical picture at a forward multiple of 25.6x means a rich multiple can persist absent a catalyst but creates meaningful downside if expectations are missed. Engine gate (failed) | Price momentum recovers above the 4.5 threshold and the stock closes above the near-term price target of $87.23 for 3 consecutive weeks, confirming both technical and fundamental improvement. | →Stable |
| CounterThree of the last four quarters produced positive earnings surprises averaging approximately 5.3%, and the stock remains above its 200-day moving average — the fundamental delivery record may eventually reassert itself over the near-term technical softness. | ||
Three earnings beats in the last four quarters with an average positive surprise of approximately 5.3% demonstrate a pattern of outperforming consensus that provides a partial offset to the valuation and momentum headwinds facing the stock. Earnings | The beat streak extends to 4 of 5 quarters with average positive surprise maintained above 3%, sustaining the fundamental credibility that supports the premium multiple. | ↓Deteriorating |
| CounterThe one miss in the sequence came in at -6.3% below estimate, showing the earnings record is not immune to setbacks; a second miss could trigger a multiple compression event given the already thin margin between price and target. | ||
Gross and operating margins both score at their maximum level with a Piotroski F-Score of 8 out of 9, placing this among the highest-quality franchises in the medical device space and providing meaningful cushion against temporary revenue setbacks.
→StableQuality breakdown
- Expectation
- Margins noted as strong at the 17% level are maintained or improved over the next 12 months, and the Piotroski F-Score remains at 7 or above, confirming durable financial health.
CounterA product revenue concentration of 74% in a single franchise means any clinical complication, regulatory action, or competitive entry affecting that category could compress these margins sharply, with limited business diversification to absorb the impact.
With approximately 74% of revenues concentrated in one product category and 58% in a single geography, any clinical setback, reimbursement change, or competitive displacement in the core franchise would have an outsized impact on overall results with no material offset from other lines of business.
↑ImprovingBear case
- Expectation
- Revenue from the leading product category declines to represent less than 65% of total sales within 2 fiscal years as the broader portfolio grows, reducing single-product dependency.
CounterThe bull case highlights a high-quality business, and best-in-class margins among peers suggest the leading product has established durable commercial economics that may limit the likelihood of rapid substitution.
Price momentum has fallen to 3.2, below the 4.5 acceptable threshold, while volume is flowing out of the stock — a deteriorating technical picture at a forward multiple of 25.6x means a rich multiple can persist absent a catalyst but creates meaningful downside if expectations are missed.
→StableEngine gate (failed)
- Expectation
- Price momentum recovers above the 4.5 threshold and the stock closes above the near-term price target of $87.23 for 3 consecutive weeks, confirming both technical and fundamental improvement.
CounterThree of the last four quarters produced positive earnings surprises averaging approximately 5.3%, and the stock remains above its 200-day moving average — the fundamental delivery record may eventually reassert itself over the near-term technical softness.
Three earnings beats in the last four quarters with an average positive surprise of approximately 5.3% demonstrate a pattern of outperforming consensus that provides a partial offset to the valuation and momentum headwinds facing the stock.
↓DeterioratingEarnings
- Expectation
- The beat streak extends to 4 of 5 quarters with average positive surprise maintained above 3%, sustaining the fundamental credibility that supports the premium multiple.
CounterThe one miss in the sequence came in at -6.3% below estimate, showing the earnings record is not immune to setbacks; a second miss could trigger a multiple compression event given the already thin margin between price and target.
Per-dimension breakdown
Quality
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.5 |
| ROA | 5.5 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 8.7 |
| Current ratio | 8.6 |
| FCF quality | 6.1 |
| Moat | 7.9 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
- ▸Strong margins: 17%
- ▸Wide economic moat
- ▸Strong Piotroski F-Score: 9/9
- ▸High-quality business
Growth
5.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.7 |
| EPS growth | 3.6 |
Momentum
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.1 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 4.1 |
- ▸Uptrend pullback (RSI 34) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 7.4 |
| erm sentiment | 4.8 |
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $6,852,175 (0.014% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.8 |
| quality rank | 7.7 |
| growth rank | 6.5 |
- ▸Best-in-class margins
- ▸Conservative debt levels
Technical
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.5 |
| support resistance | 8.9 |
| 52w position | 7.6 |
| gap | 6.0 |
Risk (lower is worse)
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 8.6 |
| volatility | 5.5 |
| put call | 10.0 |
| implied vol | 6.4 |
| max pain risk | 7.0 |
| beta | 7.9 |
| debt equity | 9.7 |
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 5.2 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 1 days
How the verdict was assembled
Engine trigger
Earnings in 1 day. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCKPassed (4)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:3.4<4.5
- ASYMMETRY:0.9<1.5@spot
- EARNINGS_PROXIMITY:1d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.95
Upside
+5.4%
Downside
5.6%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeTemporary headwind — High quality (7.6) with weak momentum (3.4)
SuitabilityModerate — Balanced profile
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 1 day. Wait until post-earnings. The 10-dimension scores remain Technical at 8.0 (strongest), but MOMENTUM:3.4<4.5 also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Technical at 8.0, Risk (lower is worse) at 8.0, and Quality at 7.6; the weakest are Momentum at 3.4, Value at 4.1, and Growth at 5.2. The V9 engine flagged 3 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.95 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Best In Class Margins Quality
Trip ifPiotroski F-Score falls below 6 out of 9 for 2 consecutive quarters.
- P2Single Product Concentration Risk
Trip ifRevenue from the leading product category falls below 65% of total revenues for 2 consecutive fiscal years.
- P3Rich Valuation Weak Momentum
Trip ifPrice momentum rises above 4.5 and stock holds above $87.23 for 3 consecutive weeks.
- P4Consistent Earnings Beat Pattern
Trip ifEPS surprise falls below 0 for 2 consecutive quarters, breaking the consistent beat pattern that provides a partial offset to valuation and momentum headwinds.